174 related articles for article (PubMed ID: 8491233)
21. Comparison of nicorandil and atenolol in stable angina pectoris.
Hughes LO; Rose EL; Lahiri A; Raftery EB
Am J Cardiol; 1990 Sep; 66(7):679-82. PubMed ID: 2144705
[TBL] [Abstract][Full Text] [Related]
22. Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris.
Ogino K; Osaki S; Noguchi N; Kitamura H; Omodani H; Kato M; Hisatome I; Matsumoto T; Kinugawa T; Miyakoda H
Eur J Clin Pharmacol; 1995; 48(3-4):189-94. PubMed ID: 7589040
[TBL] [Abstract][Full Text] [Related]
23. Chronic effects of nicorandil on exercise tolerance in patients with stable effort angina pectoris.
Hiasa Y; Hamai K; Wada T; Aihara T; Bando M; Nakai Y; Kataoka Y
Tokushima J Exp Med; 1989 Dec; 36(3-4):65-70. PubMed ID: 2534651
[TBL] [Abstract][Full Text] [Related]
24. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
Frampton J; Buckley MM; Fitton A
Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
[TBL] [Abstract][Full Text] [Related]
25. [Clinical use of potassium channel activators in angina pectoris: efficacy and tolerance].
Specchia G; Marsico F; Micheletti T; Bona M
Cardiologia; 1995 Dec; 40(12 Suppl 1):91-5. PubMed ID: 8998788
[No Abstract] [Full Text] [Related]
26. [Ischemic heart disease evaluated by exercise stress thallium-201 myocardial scintigraphy: a comparison of SPECT and bull's eye display].
Hazaki R; Naruse H; Ohyanagi M; Kawamoto H; Tateishi J; Yasutomi S; Fujitani K; Iwasaki T; Fukuchi M
J Cardiol; 1989 Sep; 19(3):679-86. PubMed ID: 2641762
[TBL] [Abstract][Full Text] [Related]
27. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
Roland E
Eur Heart J; 1993 Jul; 14 Suppl B():48-52. PubMed ID: 8370373
[TBL] [Abstract][Full Text] [Related]
28. Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism.
Kinoshita M; Hashimoto K; Ohbayashi Y; Inoue T; Taguchi H; Mitsunami K
Am J Cardiol; 1989 Jun; 63(21):71J-74J. PubMed ID: 2525330
[TBL] [Abstract][Full Text] [Related]
29. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy.
Krumenacker M; Roland E
J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S93-102. PubMed ID: 1282184
[TBL] [Abstract][Full Text] [Related]
30. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris.
Silke B; Verma SP; Ali MS; Goldhammer E; Taylor SH
Am J Cardiol; 1989 Jun; 63(21):49J-55J. PubMed ID: 2525326
[TBL] [Abstract][Full Text] [Related]
31. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease.
Goldschmidt M; Landzberg BR; Frishman WH
J Clin Pharmacol; 1996 Jul; 36(7):559-72. PubMed ID: 8844437
[TBL] [Abstract][Full Text] [Related]
32. Nicorandil: animal pharmacology.
Sakai K
Am J Cardiol; 1989 Jun; 63(21):2J-10J. PubMed ID: 2525321
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology and therapeutic effects of nicorandil.
Kinoshita M; Sakai K
Cardiovasc Drugs Ther; 1990 Aug; 4(4):1075-88. PubMed ID: 2150592
[TBL] [Abstract][Full Text] [Related]
34. [Quantitative assessment of improvement in perfusion after coronary bypass grafting: assessed by thallium-201 bull's eye subtraction polar map method].
Shindo M; Tamaki N; Takahashi N; Kawamoto M; Ohtani H; Yonekura Y; Nohara R; Kambara H; Ban T; Konishi J
Kaku Igaku; 1993 Jul; 30(7):743-51. PubMed ID: 8377297
[TBL] [Abstract][Full Text] [Related]
35. [Quantification of reversible perfusion abnormality using exercise-stress thallium SPECT before and after coronary revascularization].
Nagao K; Nakata T; Tsuchihashi K; Kobayashi H; Hase M; Hikita N; Tanaka S; Kubota M; Tsuda T; Iimura O
Kaku Igaku; 1994 Apr; 31(4):337-45. PubMed ID: 8196230
[TBL] [Abstract][Full Text] [Related]
36. Coronary microvascular response to intracoronary administration of nicorandil.
Hongo M; Takenaka H; Uchikawa S; Nakatsuka T; Watanabe N; Sekiguchi M
Am J Cardiol; 1995 Feb; 75(4):246-50. PubMed ID: 7832132
[TBL] [Abstract][Full Text] [Related]
37. Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA.
Fioretti PM; Pozzoli MM; Ilmer B; Salustri A; Cornel JH; Reijs AE; Krenning EP; Reiber JH; de Feyter PJ; Roelandt JR
Eur Heart J; 1992 Feb; 13(2):213-9. PubMed ID: 1555619
[TBL] [Abstract][Full Text] [Related]
38. Anti-ischaemic actions of potassium channel openers in experimental myocardial ischaemia/reperfusion injury in dogs.
Auchampach JA; Gross GJ
Eur Heart J; 1993 Jul; 14 Suppl B():10-5. PubMed ID: 8370365
[TBL] [Abstract][Full Text] [Related]
39. Effects of nicorandil on kinetics of oxygen uptake at the onset of exercise in patients with coronary artery disease.
Koike A; Hiroe M; Yajima T; Adachi H; Shimizu N; Kano H; Sugimoto K; Miyahara Y; Korenaga M; Marumo F
Am J Cardiol; 1995 Sep; 76(7):449-52. PubMed ID: 7653442
[TBL] [Abstract][Full Text] [Related]
40. Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test.
Kato K; Asanoi H; Wakabayashi C; Hosoda S; Shiina A; Hosono K; Kurita A; Seki K; Ishida K; Kuroiwa A
J Cardiovasc Pharmacol; 1987; 10 Suppl 8():S98-103. PubMed ID: 2447432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
